The Shingrix from GSK PLC - two-dose shingles protection reshapes adult vaccines

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-25, 22:37. Details in the imprint.

Shingrix from GSK lands in the consultation room as a small, frosted vial that pharmacists crack open with a practiced twist, mix, and draw up into a syringe. A brief sting in the upper arm, 10 seconds of pressure, and the appointment is done.

How Shingrix is built

Shingrix is a recombinant zoster vaccine that uses a varicella zoster virus glycoprotein combined with GSK’s AS01B adjuvant to trigger a strong immune response. It is given as a 0.5 ml intramuscular injection, usually in the deltoid muscle of the upper arm.

The schedule requires two doses, typically two to six months apart, to complete the primary course for adults 50 years and older. Immunologist Dr. Thomas Breuer, formerly GSK’s Chief Medical Officer, has repeatedly highlighted that adherence to the two-dose series is key to the durable protection Shingrix aims to deliver.

Efficacy and side effects

In large phase III trials, Shingrix showed vaccine efficacy above 90 percent against shingles in adults aged 50 and over, and around 89 percent in those over 70. Protection remained above 84 percent over at least four years of follow up.

On the flip side, recipients often report local pain, redness and swelling at the injection site, along with fatigue and muscle aches in the first two days after vaccination. Pharmacist-led clinics describe the arm as feeling “heavy and warm”, especially after the second dose, but symptoms usually resolve within a few days.

Who GSK is targeting

Regulators such as the US FDA and the European Medicines Agency have approved Shingrix for adults aged 50 years and older, and for some immunocompromised adults from 18 years. National immunization committees in countries like the US, UK, Germany, and Canada have recommended the vaccine as the preferred option against shingles in eligible age groups.

GSK has also pushed hard into pharmacy chains and primary care networks, with former vaccines president Roger Connor calling Shingrix a pillar of the group’s adult immunization strategy in recent investor updates. The focus is on people who remember a parent’s painful shingles rash and want to avoid the same experience.

Market performance and pricing

GSK reported Shingrix sales of £3.0 billion in 2023, up strongly year-on-year as demand recovered from the pandemic and new markets opened. Management has signaled ambitions to grow vaccines, led by Shingrix, to more than £10 billion in annual revenue by 2031.

Pricing varies by market: in the United States, the list price per dose is around 180 dollars, though insurers and public programs often negotiate lower net prices. In Europe, reimbursement schemes and negotiated tender prices mean patients usually see only a co-pay or no direct bill at all.

Where Shingrix is available

Shingrix is widely available in North America, much of Europe, parts of Asia-Pacific and Latin America, generally through primary care physicians, specialist travel clinics, and large retail pharmacies. In Germany, it can be ordered via pharmacies with a prescription and administered in a doctor’s office or a vaccination clinic, depending on regional rules.

In the UK, where GSK is headquartered, Shingrix is now used in the National Health Service shingles immunization program for older adults. The NHS sends out quiet, official letters, and GPs like Dr. Sarah Jarvis describe full clinics of grey cardigans and rolled-up sleeves on “zoster days”.

Context for investors

For GSK, Shingrix sits alongside respiratory and HIV medicines as a key growth driver in the post-consumer-health split era. On 2026-06-25, GSK PLC shares (ISIN GB0009252882) traded on the London Stock Exchange around 1,939 pence, according to current market data.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.